Having successfully expressed proteins in the chloroplasts of tobacco and other crops, Chlorogen will now focus on developing an economical method to extract the proteins for pharmaceutical use. Longer-term, Chlorogen plans to license its technology to improve agricultural products, such as insect-protected and herbicide-tolerant crops.

Chlorogen has many potential products in its pipeline. These include proteins to fight cancer, liver diseases and diabetes, for use as a blood-extending agent and to produce a vaccine against the bioterrorism agents anthrax and plague. The company already has expressed these proteins in transformed seeds ready for scale-up.

The Nidus Center for Scientific Enterprise, a biotechnology incubator in St. Louis, will be headquarters for Chlorogen, whose scientists will conduct research in the center's state-of-the-art laboratories. Chlorogen also will collaborate with scientists at the Donald Danforth Plant Science Center in St. Louis.

'"/>

Contact: Barb Abney
bcompton@mail.ucf.edu
407-823-5139
University of Central Florida
6-Aug-2003

Page: 1 2 3 4
Related biology news :

1. First glimpse of DNA binding to viral enzyme
2. First clinical study of new pediatric croup vaccine shows safety, tolerability in adults
3. 2nd media alert First Scientific Conference on Childhood Leukaemia
4. First International Scientific Conference on Childhood Leukaemia
5. First ever standards linking climate change, biodiversity and poverty seek global peer review
6. First genetic comparison of purebred domestic dogs produces surprises
7. First time in the U.S.: Saint Louis University tests third-generation vaccine against smallpox
8. First target for childhood malaria vaccine
9. First study of resveratrol dietary supplement finds effect on breast and prostate cancers unlikely
10. First flavors form a lasting impression
11. STN International launches Derwent World Patents Index First View